cookie

Translate

lunedì 23 gennaio 2017

Cannabis terapeutica: il cavallo di Troia delle coscienze

Nonostante i molti eroi presenti sul campo, la guerra di Troia fu vinta grazie a un cavallo di legno, a un inganno.
La guerra è guerra si dirà e di fronte allo sfacelo delle politiche proibizioniste fa finalmente tirare un sospiro di sollievo (non solo figurato per le persone affette da patologie alleviabili attraverso l’uso di cannabis) vedere che, dopo decenni, si sta producendo un lento, ma inesorabile cambiamento di coscienza rispetto al consumo di questa benefica pianta.
La regolamentazione dell’uso terapeutico delle infiorescenze non risolve, è vero, le profonde contraddizioni dell’odierna politica repressiva; non aiuta chi è in carcere per “reati” legati alla cannabis, ma è un passo avanti, che non possiamo che salutare favorevolmente, nell’enorme palude giuridico-morale nel quale la comunità internazionale sguazza da tempo rispetto alle politiche antidroga.
Finalmente è riconosciuta la proprietà medicinale della pianta e questa è una vittoria non da poco in un tempo di caccia alle streghe come il nostro; questa semplice verità era conosciuta da millenni, ma è stata ri-conosciuta solo recentemente dalla stragrande maggioranza degli scienziati odierni; questo ritardo mentale-storico fa relativizzare anche la guerra di Troia, scoppiata per una donna, che durò molto tempo secondo i canoni di allora, dieci anni, ma che rimane sempre una bazzecola rispetto all’ottusità e la malafede delle nostre classi politiche e alle sofferenze che, perciò, sono state patite da molti in almeno mezzo secolo di repressione.
Recenti articoli apparsi su Repubblica.it e su siti come Farmagalenica.it, tra gli altri, mi hanno indotto a fare alcune ricerche on-line sulla produzione, la distribuzione, la qualità e il prezzo della cosiddetta “cannabis terapeutica” o, per meglio dire, legale.
Mi sono concentrato sui prodotti dell’azienda Bedrocan BV, sia perché è un‘azienda leader del mercato europeo, sia perché, con viva curiosità ci tocca attendere, per la commercializzazione del prodotto delle prime colture effettuate dal laboratorio farmaceutico-chimico militare di Firenze, la fine di Gennaio 2017.
La Bedrocan produce sei tipi di cannabis medicinale: Bedrocan (thc 22% cbd?), Bedrobinol (thc 13,5% cbd > 1%) , Bediol (thc 6,5%, cbd 8%), Bedica (thc 14%, cbd 1%), Bedrolite (thc 0,4, cbd 9%), Bedropur (thc ? Cbd >1) le quali sono tutte marchi registrati e una serie di estratti in etanolo corrispondenti alle piante patentate.
I fiori essiccati vengono venduti in pacchetti da cinque grammi ciascuno, a un prezzo finale per il consumatore che oscilla tra i 18 e i 22 euro al grammo.
La richiesta di prodotti può essere effettuata solo da farmacie o enti ospedalieri, previa compilazione di un documento specifico e la consegna avviene , secondo disponibilità, nel limite di due mesi dall’ordinazione del quantitativo.
Le analisi garantite sui fiori riguardano il contenuto di terpeni del prodotto finito, l’analisi microbiologica per identificare batteri o muffe e la qualità chimica, per identificare la presenza di pesticidi, metalli pesanti o micotossine.
Non sono un chimico e addentrarmi più a fondo nella materia utilizzando questi dati non rientra nelle mie capacità, solamente una cosa mi balza immediatamente all’occhio.
La liberalizzazione della cannabis cosiddetta “terapeutica” ha creato un nuova classe di esperti tra coloro, scienziati e militari, che durante l’ultimo mezzo secolo hanno avallato, con studi insufficienti o del tutto inventati, e represso l’uso di una pianta che essi stessi oggi riconoscono come medicinale, ma non per questo premono perché sia al più presto varato un provvedimento per la depenalizzazione dell’uso della cannabis in generale.
Oggi abbiamo la fortuna di poter disporre di dati effettivi riguardo i benefici, economici e non, che la legalizzazione della cannabis ha prodotto su molti territori che l’hanno voluta introdurre; il volume di affari sembra promettente ed è naturale che da più parti lo si guardi con occhi avidi.
Almeno per quanto riguarda la cannabis terapeutica sembra conveniente sottrarre clienti al mercato nero (anche se i prezzi sembrano francamente proibitivi per il consumatore medio) questo comporta però, a quanto pare fino ad ora, un’elevata specializzazione della filiera di produzione della cannabis, che può essere appannaggio solo di chi dispone degli strumenti atti per legge a poter garantire le analisi indispensabili alla messa in vendita del prodotto.
A questo punto sembrerebbe che non abbiano legalizzato una “parte” di erba, ma che abbiano inventato un nuovo tipo di proibizionismo, nel quale, ancora una volta, nascondere conoscenza (perchè patentare strain terapeutici? solo perchè si hanno concessioni internazionali monopolistiche?) e fare informazione di parte sia ancora il nucleo di un meccanismo di potere consolidato, che sarà difficile da sconfiggere senza un completo ribaltamento della visione dell’uomo, se non del mondo.
Relegando la ricerca e la coltivazione a determinate istituzioni ancora una volta, con poco, viene tolta voce in capitolo a tutti coloro che inquadrano questa lotta per la legalizzazione della cannabis nell’ottica delle lotte per i diritti umani, dimenticando che inserire la cannabis tra le piante medicinali e non tra le droghe leggere significa non solo spostare un segno da una tabella all’altra, ma influire in maniera determinante nella vita di moltissimi individui.
Timeo Danaos et donas ferentes, non mi fido dei greci, anche se portano doni.
Solo una legalizzazione generale della cannabis potrà portare reali benefici alle moltissime persone che in carcere, in ospedale o per strada soffrono di questa isteria collettiva che si chiama proibizionismo ed è l‘unica alternativa alla creazione di un nuovo monopolio industriale-farmaceutico, basato su di una pianta che, ricordiamolo, fino a poco si voleva eliminare dalla faccia della Terra.
La guerra di Troia, che infiniti lutti addusse agli Achei, venne vinta con l’inganno di un cavallo di legno: facciamo attenzione che questi insufficienti regali non finiscano per convincerci e farci accontentare.
Carlo Hermann

Cannabis terapeutica: il cavallo di Troia delle coscienze

giovedì 19 gennaio 2017

Cannabis Science Inc. (CBIS) and Dana Farber/Harvard Cancer Center (DF/HCC) Announce Joint Research and Drug Development Agreement; Collaborative Research Agreement

BOSTON, MA--(Marketwired - Jan 6, 2017) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabinoid-based medications, is proud to announce a collaborative research agreement with Dana Farber/Harvard Cancer Center (DF/HCC). The agreement lays the foundation for a cooperative research initiative to explore and develop new cannabinoid medicines to fight cancer. This agreement is also the first step in the development of clinical trials that will lead to approval of successful cannabinoids by the FDA.




"We believe that collaborative cutting-edge work is the most powerful approach in fighting cancer. This collaborative agreement brings together the expertise of a leading Cannabis Research Company, Cannabis Science, and the research strength of Dana Farber/Harvard Cancer Center. I can see how this collaboration with Cannabis Science will grow as we work together for commercialization of joint research successes, with ultimate goal of translating these successes to benefit cancer patients in the USA and across the globe. So, I'm excited to get started setting up what could become a leading Cannabis Science Institute lab under my direction here at the Harvard Institute of Medicine. Under this agreement, Cannabis Science will have access to the best expertise within Dana Farber/Harvard Cancer Center to help develop multiple preclinical and clinical cannabinoid compounds. As we progress, we can bring cannabinoid cancer compounds to clinical trials and to FDA approval process quickly and efficiently. So many patients still die of cancer, hence our urgency and obligation to swiftly pursue cutting-edge research that can benefit patients," stated, Professor Wilfred Ngwa, PhD., Director, Global Health Catalyst, Dana Farber/Harvard Cancer Center.

"The goal of this research project is to develop and investigate the use of Cannabinoids in the treatment of a variety of cancers, and investigate the synergistic impact of cannabinoids when used together with standard and novel anti-cancer regimens. We believe that cannabinoid therapeutics must be refined and we hypothesize that cannabinoids can optimize standard and novel anti-cancer treatments, including those that train the immune system to fight cancer metastasis, i.e. cancer spread to other parts of the body. Metastasis accounts for over 90% of cancer deaths and associated pain and suffering; hence, if we are successful, this could lead to major increase in survival and quality of life for cancer patients in the USA and across the world.

"The results of our work should give us a much better understanding of how cannabinoids interact with cancer and immune cell populations, and to leverage this knowledge to develop refined and optimized combination of cannabinoids, specifically designed to combat the spread of cancer. We will extract/analyze and refine cannabinoids for in-vivo investigations. We will refine the cannabinoids to superior grade level for medical application and then examine their effectiveness in a precisely targeted delivery system, designed to maximize damage to cancer cells with minimal side effects.




"Findings from this collaborative research will be expeditiously submitted to leading peer-reviewed journals, and resulting publications will be widely disseminated to the public. Publications will be jointly authored with authorship credits based on contributions, as per academic standards and customs. Additionally, any treatments, inventions conceived, and other intellectual property that is the result of this collaboration will be jointly owned by the CBIS and DF/HCC, and this includes patents on medications and delivery methods," stated, Dr. Allen A. Herman, Chief Medical Officer (CMO), Cannabis Science Inc.

"We are so excited to be able to announce our collaboration with one of the most esteemed cancer research institutions in the world. 2017 is setting up to be the biggest year for the Company and Shareholders since our inception in 2009, and this collaboration with DF/HCC is one more step that Cannabis Science is taking to increase shareholder value. Our intentions are simple: provide improved quality of life, and create knowledge. This is a new kind of collaboration between a comprehensive bricks and mortar cancer research center like DF/HCC that has years of expertise and understanding of cancer research and treatments, and a cutting-edge cannabinoid research and development Company like CBIS with aggressive plans to leverage our expertise in the chemical makeup of cannabinoids to develop highly effective cannabinoid-based cancer treatments", stated Cannabis Science Inc., President & CEO, Mr. Raymond C. Dabney.

Cannabis Science Inc. (CBIS) and Dana Farber/Harvard Cancer Center (DF/HCC) Announce Joint Research and Drug Development Agreement; Collaborative Research Agreement

domenica 15 gennaio 2017

I dati del DPA, sarebbe giusto fare chiarezza

E' uscita la relazione del DPA che mette in mostra i dati relativi al mercato della cannabis. Stimano un mercato che vale 4 miliardi di euro. Il dato, che è una stima, perchè non si basa su dei consumi effettivamente registrati, e probabilmente poco o per nulla attendibile.

Nella presentazione portata alla commissione giustizia nel 2013, L' economia della sicurezza pubblica, sulla basa dei dati riscontrabili nella "Relazione Europea sulla droga" 2013 e il report "EU Drug markets Report" emergono numeri diversi.

L' Italia era primo consumatore europeo di hashish con una quota pari al 30% di un mercato stimato in 1300 tonnellate e il terzo mercato per infiorescenze di cannabis ( 1200 tonnellate consumate annualmente in europa). Sulla base di questi dati emerge un fatturato annuo, del mercato italiano della cannabis di circa 5.6 miliardi di euro.

Quindi la domanda è: se i dati del 2013 europei parlano di un mercato di quasi 6 miliardi di euro solo per la cannabis e i derivati, da dove arrivano i numeri del DPA di oggi? Se i dati sono stati presi dall' ISTAT c'è un errore del circa 50% sulle stime (se si considera di passare da 4 miliardi a 6).

In Europa, i dati italiani sulle statistiche delle droghe, non sono ritenuti più attendibili da anni; sulla base di cosa si continuano a tirare fuori numeri dal cilindro?

giovedì 12 gennaio 2017

Senate Banking Committee Could Pave the Way to a Bankable Marijuana Industry


NEW YORK, January 11, 2017 /PRNewswire/ --

NetworkNewsWire.com News Coverage: Last month, a letter signed by 10 U.S. senators arrived on the desk of Jamal El-Hindi, the acting director of the Financial Crimes Enforcement Network (FINCEN), requesting guidance on how banking services might be offered to "indirect businesses" - such as SinglePoint, Inc. (OTC: SING), Medical Marijuana, Inc. (OTC: MJNA) and Cannabis Science, Inc. (OTC: CBIS) - that serve the state-sanctioned marijuana industry. The implications of such guidance also carry considerable potential for banking players ranging from small financial institutions to bellwether banks like Bank of America (NYSE: BAC) and Citigroup (NYSE: C).


The letter came at the prompting of U.S. Senator Elizabeth Warren, D-Mass, a member of the Senate Banking Committee that oversees federal monetary policy, banking regulation and issues affecting the U.S. currency. It's a widely applauded push, and SinglePoint, Inc. for one, is banking on this initiative to clear the way for payment processing providers, such as its SingleSeed Payments subsidiary, to offer an array of payment and transaction services to marijuana shops and dispensaries.

According to a recent report in the Houston Chronicle (http://nnw.fm/qq6NB), this action is part of a wider effort by many policymakers to regularize the patchwork legal nature of the $7 billion marijuana industry, marked by a lack of banking options that forces marijuana businesses "to rely solely on cash, making them tempting targets for criminals."

Although 28 states and the District of Columbia have now legalized either adult recreational or medical use of marijuana, the Drug Enforcement Administration (DEA) still classifies it as a Schedule I substance "with no currently accepted medical use and a high potential for abuse." Yet, there is growing evidence in the medical profession and the general population that marijuana has beneficent therapeutic properties.

Companies like Cannabis Science, Inc. (OTC: CBIS) have set out to develop novel cannabinoid-based therapies for unmet medical needs, while others like Medical Marijuana, Inc. (OTC: MJNA) - the first publicly traded cannabis company - focuses on a variety of cannabinoid-based applications for consumer and medical markets.

In a collection of 60 peer-reviewed studies on medical marijuana (http://nnw.fm/75PYw) examining the employment of marijuana in the treatment of a long list of ailments - including amyotrophic lateral sclerosis (ALS), cancer and HIV/AIDS - 41 (68.3%) demonstrated positive results. Another 14 (23.3%) were inconclusive, and five (8.3%) of the trials reported negative outcomes.

Senator Warren has argued that loosening the restrictions that force marijuana business to transact in cash payments has a number of advantages.

"You make sure that people are really paying their taxes. You know that the money is not being diverted to some kind of criminal enterprise. And it's just a plain old safety issue. You don't want people walking in with guns and masks and saying, 'Give me all your cash.'"

There is some hope that the barriers preventing payment services providers like SingleSeed from doing business with marijuana establishments will be removed. FINCEN previously lent a sympathetic ear to similar pleas. In February 2014, the bureau offered guidance on how financial institutions could provide services to marijuana-related businesses consistent with their Bank Secrecy Act obligations.

That earlier guidance appears to have been tailored to businesses that dealt directly in marijuana like pot shops and marijuana dispensaries. It did not address the plight of the indirect businesses that service the marijuana industry, leaving it up to individual financial institutions to determine how to classify and treat indirect businesses.

Tossing the buck to financial institutions has had paltry success: "the number of banks and credit unions willing to handle pot money rose from 51 in 2014 to 301 in 2016," a figure that appears encouraging until placed in a wider context. There are 11,954 federally regulated banks and credit unions. In general, it's still an area dominated by small state-chartered banks and credit unions. Supporters of a bankable marijuana industry, however, see an inevitable day when large banks like Bank of America and Citigroup will offer full banking services to the cannabis industry.

When that day comes, financial technology (fintech) companies will have the chance to capitalize on a monstrous opportunity. SinglePoint's SingleSeed Payments subsidiary, for example, is already primed to offer ATM, Pay-by-Text[TM] and text message marketing to the cannabis industry. As it stands, progressive fintechs are in a similar quandary to their federally regulated counterparts and look forward to further guidance from FINCEN.

For more information, visit Singlepoint, Inc. (SING)

For more information about NetworkNewsWire, please visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

DISCLAIMER: www.NetworkNewsWire.com is source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with NetworkNewsWire (NNW) or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. The companies that are discussed herein may or may not have approved the statements made in this release. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW & FNM undertakes no obligation to update such statements.

Media Contact e-mail: editor@financialnewsmedia.com U.S. Phone: (954)345-0611

SOURCE NetworkNewsWire.com


Senate Banking Committee Could Pave the Way to a Bankable Marijuana Industry

lunedì 9 gennaio 2017

Medical Marijuana Inc (OTCMKTS:MJNA) Is Building A Medical Marijuana Empire South Of The Border

By Chris Sandburg / in Momentum & Growth, Momentum Stocks, Sector Watch, Stocks / on Thursday, 29 Dec 2016 10:10 PM


Medical Marijuana Inc (OTCMKTS:MJNA) continues to climb higher into the close of 2016, as the company continues to push out updates relating to its operations. The company ran up into the November ballot along with the rest of the industry, but dipped into the latter part of the month, as traders took profits off the table. In our last coverage of this one, early December, we concluded that the company had plenty of upside potential left, and that it looked like a nice near to medium term momentum play on the back of this assumption.

We pointed out that the then-recent filing of an IP application by a a company in which Medical Marijuana holds a circa 35% position, Axim Biotechnologies Inc (OTCMKTS:AXIM), moved the latter, but failed to really move the latter, and that this was a bit of a red flag. Not enough to put us off completely, but enough to temper enthusiasm.

Anyway, that was then, this is now. What’s happened over the last few weeks, and what does it mean?

The company has focused on expansion in the central and south American markets, and it’s from this expansion that much of the value-add seen over the last few weeks derives. First up, Medical Marijuana announced that the cannabis regulations had been relaxed in Mexico, and that it was looking to build on its operations in the nation by expanding its full range into the Mexican market. The current product it sells into the space is a product called Real Scientific Hemp Oil-X, and it was the first-ever federally approved CBD product in Mexico. It’s got a portfolio of alternative Real Scientific products waiting in line to get in the country, and now the regulations have eased, the company should be able to start generating multiples of its Mexican revenues near term.

The next major update detailed the expansion of HempMeds (which is the subsidiary that sells the above mentioned product into the Mexican market) into Chile and Argentina. Shortly after that, we got word that the same product had started being sold in Brazil, so that gives HempMeds, and by proxy, Medical Marijuana, a solid presence south of the US border.

For us, these are all great moves, but we’re looking to the US as the market that’s going to drive real value, and as yet, things aren’t moving overly fast. So, that’s what we’re looking for next. Of course, the market is a little less mature in many of the US markets, but in places like California, we feel there is plenty of room for fast expansion. As such, we’re keeping an eye on releases purporting to these above-the-border markets before confirming a long term bias.

With that said, to build a medical marijuana operation in places like Mexico and Brazil is not an easy task, and that Medical Marijuana is making considerable inroads towards this task strengthens a near term these, given its current market capitalization. Weighing the company up against some of its peers in the space, Medical Marijuana has some real positives. It’s generating revenues, it’s got an international distribution network in place, and it’s got a great product in a rapidly growing, yet still very much nascent, industry.

Cash isn’t great, so we expect some degree of dilution if the company is to capitalize on its potential, but so long as management can put together a raise structure that isn’t overtly toxic to shareholders, there’s a definite momentum opportunity on this one.

Look to the continued stream of business development updates from South America to support near term value, and updates relating to the US operations as indicative of longer term potential.


mercoledì 4 gennaio 2017

Six Predictions For The Marijuana Industry In 2017

I write about retail and cannabis.  
This year saw big election wins for marijuana in several states. In addition, Colorado crossed the $1 billion mark for annual marijuana sales. Now a new year is almost here and a new presidential administration for the cannabis industry to navigate. It's time to look ahead and see what's in store for the cannabis industry in 2017.
The two biggest areas of focus for the upcoming year are California and Jeff Sessions. With California's recreational marijuana market in the building phase, many in the industry will be watching for progress throughout the year. Another big center of attention will be the appointment of Jeff Sessions as U.S. Attorney General. This will keep the industry on heightened alert for any changes in law enforcement.  Aside from those two topics, here are some of the industry’s biggest predictions for the 2017.
  1. Los Angeles Will Become The Marijuana Capital
Move over Denver, Adam Bierman Chief Executive Officer of cannabis investment firm MedMen Capital believes that the City of Angels will steal the spotlight from the Mile High City. Bierman said that by some estimates, Los Angeles's medical marijuana market alone is already close to $1 billion, easily overshadowing Colorado’s entire market. The city is expected to pass an ordinance in 2017 that will clear the path for a proper licensing program and open up the recreational market. Bierman said that capital is flowing into the area for local ventures as investors begin to smell money in the emerging market.
  1. A Sports League Will Green Light Marijuana
Bierman believes that in 2017 a major sports league will approve the use of cannabis for medical purposes. Many professional athletes have turned to using cannabis to treat pain and head injuries and are rejecting prescribed opiates. With medical marijuana legal in 29 states, the players are pushing to be treated just like other patients.
  1. A Primetime Network Show With A Marijuana Theme
With many polls showing that most Americans approve of legalizing marijuana, it won't be long before a major network will use marijuana as a backdrop. It's been over a decade since Showtime had a hit with Weeds. That series focused on a suburban mom that sold pot to make ends meet. It was considered ground breaking at the time with its taboo topic. Now HBO has High Maintenance and MTV's got Mary + Jane. Adam Scott from Parks and Recreation got a green light from NBC to develop a show called Buds about a dispensary in Denver. There isn't any timeline yet as to when the comedy could hit the air waves.
  1. An Increase In Interest For Synthetic CBD
With the Hemp Industries Association and the DEA battling over the legality of cannabis extracts like cannabinoids or CBD, there is an expectation for increased interest in synthetic cannabinoids. Seth Yakatan, the chief executive officer of biotech company Kalytera, said, “With AG Sessions and the DEA's clarification that plant derived CBD isn't legal federally, there will likely be interest in synthetic forms of CBD, which is what Kalytera has been testing the efficacy of for a few years.” Aside from the debate over whether CBD is legal or not, Yakatan is right that synthetic products do not have the legal limitations of other products. However, the synthetic products are not believed to be as effective as the natural products according to some patients. Fear over legal issues could create more demand for the synthetics.
  1. The Growth of Craft Marijuana
Sasha Kadey, Chief Marketing Officer of vaporizer distributor Greenlane, said he expects that as market supplies grow, prices will fall, causing a commoditizing effect. “This is leading to premiumization," he said. "Much like the alcohol industry experienced during its maturation, with producers now seeking to differentiate with premium packaging, brand building, so called “seed to sale” storytelling, and other value adds.” Other growers will stress their organic features, while some will push celebrity endorsements. It will be the year of the craft bud.
6. Recycling Marijuana Failures
The Cannabis Business Alliance is hoping to work with lawmakers to create options for marijuana that fails pesticide testing. Currently marijuana producers have to destroy crops that fail testing. The CBA is working towards a new rule to allow for these harvests to be turned into solvent-based concentrates that would be considered safe.